Skip to main content
Premium Trial:

Request an Annual Quote

Viaken Names New Head of Consulting Services Unit

NEW YORK, June 12 – Bioinformatics company Viaken Systems said Tuesday it had appointed Michael Provance as head of global professional services, an information technology consulting services.

Provance will take over the responsibilities of managing the services group from Stephen Gardner, Viaken's vice president and CTO. Gardner will now concentrate on developing the company’s data products business and its European operations. 

"Michael's in-depth experience in building and running professional services organizations makes him a valuable asset that will help us enhance our services side into a profitable business unit," James Serum, executive vice president and COO of Viaken, said in a statement.

"As an important part of our business model, our global professional services organization rounds out the company, providing customers with a complete, end-to-end solution," he said. 

Previously Provance worked for US Interactive, an Internet strategic consulting firm.

Viaken, of Gaithersburg, Md, resells and hosts bioinformatics software applications, providing IT bioinformatics support to customers around the world. Unlike other genomics-related Internet hubs, including those offered by DoubleTwist, Compugen, and eBioinformatics, Viaken does not develop proprietary software or content.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.